Session Information
Date: Monday, September 23, 2019
Session Title: Clinical Trials, Pharmacology and Treatment
Session Time: 1:45pm-3:15pm
Location: Agora 3 West, Level 3
Objective: Analyze the patient profiles and dynamics of utilization of Continuous Subcutaneous Apomorphine Infusion (CSAI), Levodopa-carbidopa Intestinal Gel (LCIG), and Deep Brain Stimulation (DBS) for Parkinson´s disease (PD) in Germany from 2010 – 2017.
Background: Parkinson’s disease is the most common chronic neurodegenerative movement disorder requiring intensified treatment including medical devices in advanced stages of disease. The characteristics of patients and the degree of prescription for these medical devices has not been analyzed for the German population so far.
Method: Analyses of infusion therapies and neurostimulation procedures were based upon the statistical evaluation of the German Diagnosis-Related Groups (G-DRG) data from 2010 to 2017 (DRG-statistic, Federal Statistical Office, www.destatis.de) and on structured quality reports of German hospitals according to §137 3.1 No. 4 SGB V.
Results: In 2017, 194 patients received an initial setup of a treatment with CSAI and 233 patients were monitored for their therapy in an inpatient facility. In the same year, 159 patients received an initial setup of a treatment with LCIG and 261 patients were monitored. For both CSAI and LCIG treatments both initial setups and stationary monitoring visit numbers strongly increased from 2010 to 2017. Concerning DBS, 377 patients received an implantation or replacement of a multi-channel, fully implantable and not rechargeable neurostimulator and 199 patients underwent the beforementioned procedure with rechargeable device in 2017. From 2010, patient numbers for the non-rechargeable devices remained stable but numbers for the rechargeable devices increased six fold. Interestingly, for all devices there is a strong center formation for application of these therapies throughout Germany.
Conclusion: The number of device-based therapies for PD patients strongly increases in Germany from 2010 to 2017. There is a strong development for a supra-regional formation of treatment centers. However, a significant number of centers remains with only very low procedure numbers.
To cite this abstract in AMA style:
L. Tönges, D. Bartig, C. Krogias, D. Richter. Dynamics of Device-based Treatments for Parkinson´s Disease in Germany from 2010 – 2017 [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/dynamics-of-device-based-treatments-for-parkinsons-disease-in-germany-from-2010-2017/. Accessed May 13, 2025.« Back to 2019 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/dynamics-of-device-based-treatments-for-parkinsons-disease-in-germany-from-2010-2017/